

## FAX COVER SHEET

---

**TO**

---

**COMPANY**

---

**FAX NUMBER**      19725329272

---

**FROM**                nuvscanner@gohealthurgentcare.com

---

**DATE**                2025-12-19 10:24:43 MST

---

**RE**                    Message from "Lagrangeville"

---

### COVER MESSAGE

---

This E-mail was sent from "Lagrangeville" (IM 2500).

Scan Date: 12.19.2025 12:23:54 (-0500)

Queries to: nuvscanner@gohealthurgentcare.com

# MVPFASTFAX

December 2, 2025 – 2025.59

Important News for Providers

This communication should be viewed by:

Primary Care Providers, Behavioral Health Providers, Clinical staff

## Laboratory Policy Updates Effective February 1, 2026

MVP Health Care® (MVP) is sharing Laboratory Policy updates effective February 1, 2026.

To view all current MVP Laboratory Policies, visit [mvphealthcare.com/policies](https://mvphealthcare.com/policies) and select *Laboratory Policies*. This communication lists all impacted policies and their statuses. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective February 1, 2026, and will be available for viewing 60 days prior to their effective date. Please send comments to [comments@mvphealthcare.com](mailto:comments@mvphealthcare.com) by February 1, 2026.

| Laboratory Policy Name  | Status  |
|---|---------|
| B-Hemolytic Streptococcus Testing   | Updated |
| Biochemical Markers of Alzheimer Disease and Dementia   | Updated |
| Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases                        | Updated |
| Bone Turnover Markers Testing   | Updated |
| Celiac Disease Testing  | Updated |
| Cervical Cancer Screening   | Updated |
| Diabetes Mellitus Testing   | Updated |
| Diagnosis of Vaginitis  | Updated |
| Diagnostic Testing of Common Sexually Transmitted Infections                                    | Updated |
| Diagnostic Testing of Influenza   | Updated |
| Epithelial Cell Cytology in Breast Cancer Risk Assessment                                       | Updated |
| Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing | Updated |
| Fecal Calprotectin Testing in Adults  | Updated |
| Gamma-glutamyl Transferase Testing in Adults  | Updated |
| Human Immunodeficiency Virus (HIV)  | Updated |
| Immunopharmacologic Monitoring of Therapeutic Serum Antibodies                                  | Updated |
| In Vitro Chemoresistance and Chemosensitivity Assays  | Updated |
| Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease                              | Updated |
| Metabolite Markers of Thiopurines Testing   | Updated |
| Oral Cancer Screening and Testing   | Updated |
| Pathogen Panel Testing  | Updated |
| Prenatal Screening (Nongenetic)   | Updated |
| Prostate Biopsy Specimen Analysis   | Updated |
| Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease    | Updated |
| Testing for Diagnosis of Active or Latent Tuberculosis  | Updated |
| Testing for Vector-Borne Infections   | Updated |
| Urine Culture Testing for Bacteria  | Updated |